

Alkyl Amines Chemicals Limited



Reg. Office: 401-407, Nirman Vyapar Kendra, Plot No. 10, Sector 17, Vashi, Navi Mumbai - 400 703. INDIA Tel.: 022-6794 6600 • Fax: 022-6794 6666 • E-mail : alkyl@alkylamines.com • Web: www.alkylamines.com

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2020

	Quarter ended (Except per share data) Quarter ended						
				Year ended			
Sr.	Particulars	Mar 31, 2020	Dec 31, 2019	Mar 31, 2019	Mar 31, 2020	Mar 31, 2019	
No.		Audited	Unaudited	Audited	Audited	Audited	
١.	Revenue from Operations	23,476.51	25,691.11	23,745.11	99,287.76	84,640.09	
ı. II.	Other Income	261.93	216.72	160.55	701.16	394.75	
III.	Total Revenue (I+II)	23,738.44	25,907.83	23,905.66	99,988.92	85,034.84	
		20,700	20,001.00				
IV.	Expenses				.=	10 175 51	
	Cost of Materials Consumed	11,054.36	11,445.87	13,597.46	47,621.68	48,176.61	
	Changes in Inventories of Finished Goods	(264.15)	16.02	574.90	827.78	(2,089.41)	
	and Work-in-Progress	4 605 74	1 002 70	1 264 50	C 0C4 1F	E 277.00	
	Employee benefit costs	1,695.74	1,903.79	1,264.50	6,964.15	5,277.90	
	Finance Costs	189.32	213.45	332.05	1,025.39	1,476.66	
	Depreciation and Amortisation Expense	720.25	680.26	646.40	2,690.98	2,333.68	
	Other Expenses	4,232.32	5,067.97	4,470.51	18,172.17	16,839.91	
	Total Expenses (IV)	17,627.84	19,327.36	20,885.82	77,302.15	72,015.35	
V.	Profit before Exceptional Items and Tax (III-IV)	6,110.60	6,580.47	3,019.84	22,686.77	13,019.49	
VI.	Exceptional Items (Refer Note 9)	-	3,284.16	-	3,284.16		
2000	Profit before tax (V+VI)	6,110.60	9,864.63	3,019.84	25,970.93	13,019.49	
	Tax Expense :	0,110.00	3,004.03	3,023.01	20,510.00		
VIII	Current Tax	1,453.14	1,694.50	1,088.60	5,403.55	3,619.81	
	Deferred Tax	(266.74)	100000000000000000000000000000000000000	175.93	(1,030.04)	The state of the s	
	Tax adjustments of earlier years	3.42	(30.40)	-	69.30	7.32	
_	Town defautification of contract yours	1,189.82	2,155.98	1,264.53	4,442.81	4,645.04	
IX.	Net Profit for the Period/Year (VII-VIII)	4,920.78	7,708.65	1,755.31	21,528.12	8,374.45	
Х.	Other Comprehensive Income/ (Expense)	(10.10)	(40.55)	(4.05.74)	(474.47)	(74.22	
	a) Items that will not be reclassified to profit or loss	(13.13)	(49.65)	(105.71)	(171.17)	(74.22	
	- Remeasurement gain/(losses) on defined benefit						
	plans	1.82	11.45	37.08	40.38	26.06	
	b) Income tax relating to items that will not be	1.82	11.45	37.00	40.36	20.00	
	reclassified to profit or loss	0.00	(64.60)	(25.03)	0.80	(31.81	
	c) Items that may be recycled to profit or loss	0.86	(64.69)	(25.93)	0.80	(31.61	
	- Deferred gains/(losses) on cash flow hedges	(0.40)	44.60	0.00	(0.10)	11.12	
	d) Income tax relating to items that may be	(0.19)	14.60	9.06	(0.18)	11.12	
	reclassified to profit or loss	(40.54)	(00.20)	(05.50)	(120.17)	(68.85	
	Other Comprehensive Income / (Expense) for the	(10.64)	(88.29)	(85.50)	(130.17)	(00.00)	
	period/year (Net of Tax)						
XI.	Total Comprehensive Income for the period/year	4,910.14	7,620.36	1,669.81	21,397.95	8,305.60	
						MESC	
XII.	Paid up Share Capital	1,019.82	1,019.82	1,019.82	1,019.82	1,019.82	
XIII	Face Value of Share (Rs)	5.00	5.00	5.00	5.00	2 M/5:00	
	Earnings Per Equity Share					112/10118	
	Basic (Rs)	24.13	37.79	8.61	105.55	41.06	
	Diluted (Rs)	24.06	37.69	8.58	105.27	40.95	



Notes:

1. STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT MARCH 31, 2020

	Rs. in Lakh				
	Particulars	9	As At	As At	
	r articulars	_	Mar 31,2020	Mar 31,2019	
ASS	ETS				
	-Current assets				
(a)	Property, Plant and Equipment		39,224.45	37,551.58	
b)	Capital Work-In-Progress	1	4,488.06	4,315.18	
c)	Right of Use- Lease assets		2,966.40	-	
d)	Intangible Assets		157.04	91.16	
e)	Financial Assets	1			
	(i) Investments	i	-	144.11	
	(ii) Loans	- 1	42.28	45.55	
	(iii) Other Financial Assets		252.77	285.85	
f)	Non-Current Tax Asset (Net)		445.18	356.97	
g)	Other Non-Current Assets		1,347.64	858.14	
0,			48,923.82	43,648.54	
Curi	rent assets	Ī			
(a)	Inventories	1	8,366.54	10,569.29	
(b)	Financial Assets	1	-,		
-/	(i) Trade Receivables	1	16,422.15	15,263.39	
	(ii) Cash and Cash Equivalent		3,123.86	1,933.91	
	(iii) Bank Balance	- 1	102.58	83.52	
			23.46	19.72	
	(iv) Loans	- 1	791.79	202.40	
/_\	(v) Other Financial Assets	- 1		ON 100 100 100 100 100 100 100 100 100 10	
(c)	Other Current Assets	H	584.22	3,131.43	
		-	29,414.60	31,203.66	
тот	AL ASSETS		78,338.42	74,852.20	
	JITY AND LIABILITIES				
Equ			1 000 50	1 000 50	
(a)		9	1,020.60	1,020.60	
(b)	Other Equity		52,639.06	35,478.71	
LIAI	BILITIES	ŀ	53,659.67	36,499.31	
01	n-current liabilities	- 1			
(a)	Financial Liabilities	- 1			
(d)					
	Long term Borrowings		4,752.02	7,775.37	
	(i) Secured Borrowings	and the same of	41.46	129.37	
	(ii) Unsecured Borrowings			129.57	
	(iii) Other Financial Liabilities	-	62.17	100.20	
(b)	Provisions		278.11	186.30	
(c)	Deferred Tax Liabilities		4,036.27	5,066.31	
(d)	Liabilities for Current Tax (Net)	- 1	127.47	419.38	
			9,297.50	13,576.73	
Cur	rent liabilities				
(a)	Financial Liabilities			•	
	(i) Secured Borrowings		3.87	3,508.32	
	(ii) Unsecured Borrowings		-	1,547.00	
	(iii) Lease Liability		5.63	-	
	(iv) Trade Payables		7,077.49	12,399.02	
	(v) Other Financial Liabilities		7,390.46	6,295.42	
(b)	Other Current Liabilities		341.11	560.29	
(c)	Provisions		562.70	466.11	
			15,381.26	24,776.16	
				74.075.55	
LO.	TAL EQUITY AND LIABILITIES		78,338.42	74,852.20	



2 STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2020

		Rs. in Lakhs
	For the year	For the year
Particulars	ended	ended
	2020	2019
Cash Flow from Operating Activities		
Profit before tax from continuing operations	25,970.93	13,019.49
Adjustments for :		
Depreciation and Amortization	2,690.98	2,333.68
(Gain)/Loss on disposal of assets	144.01	57.65
Exceptional Item (Gain on sale of Investment)	(3,284.16)	
Unrealized Loss/(Gain) on Foreign Exchange	331.17	570.32
Interest expense (Gross)	1,025.39	1,476.66
Interest Income	(179.51)	(31.44)
Dividend from Investments in Associates-DACL	(59.56)	(163.79)
Provision no longer required, written back	(118.48)	(51.94)
Bad Debts written off		29.39
Employee Stock Options granted	84.99	103.19
	26,605.76	17,343.21
Operating Profit before Working Capital Changes		
Adjustments for:		
(Increase) / Decrease in Other Current & Non-		
Current Financial Assets	(553.17)	(193.10)
(Increase) / Decrease in Other Current & Non-		
Current Assets	2,057.71	344.13
(Increase) / Decrease in Inventories	2,202.75	(2,051.18)
(Increase) / Decrease in Trade Receivables		
The state of the s	(1,489.93)	(3,485.54)
Increase / (Decrease) in Trade Payables	(5,321.52)	5,681.08
Increase / (Decrease) in Other Current Financial	1,285.36	(87.86)
Increase / (Decrease) in Other Current Liabilities	(219.18)	356.31
Increase / (Decrease) in Provisions	17.23	77.36
	24,585.01	17,984.41
Income taxes paid	(5,812.77)	(3,563.55)
Net Cash Flow from Operating Activities	18,772.24	14,420.86
Cash Flow from Investing Activities		
Purchase of Fixed Assets	(7,728.46)	(6,904.29)
Disposal of Fixed Assets	15.42	13.99
Interest Income	175.91	32.05
(Increase)/ Decrease in Margin Money & Fixed		
Deposits		
(having the original maturity of more than 3 months)	(19.06)	15.66
Dividend from Investments in Associates-DACL	59.56	163.79
Proceeds from Sale of Investments	3,428.27	=
Net Cash from Investing Activities	(4,068.36)	(6,678.81)
Cash Flow from Financing Activities		
Interest paid	(1,073.80)	(1,500.69)
Repayment of Non-current Borrowings	(2,919.03)	(3,456.23)
Repayment of Current Borrowings	(5,051.45)	779.40
Increase / (Decrease) in Lease Liabilities	67.80	-
Dividend and Dividend Tax Paid	(4,426.10)	(1,721.29)
Payment of Deferral Sales Tax	(111.34)	(132.77)
	(13,513.92)	(6,031.58)
Net Cash from Financing Activities		
Net Increase / (Decrease) in Cash and Cash		4 740 40
Net Increase / (Decrease) in Cash and Cash	1,189.96	1,710.48
Net Increase / (Decrease) in Cash and Cash Equivalents	1,189.96 1,933.90	1,710.48 223.42
Net Increase / (Decrease) in Cash and Cash Equivalents Cash and Cash Equivalents at the beginning of the	1,933.90	223.42
Net Increase / (Decrease) in Cash and Cash Equivalents Cash and Cash Equivalents at the beginning of the	200000000000000000000000000000000000000	
Net Increase / (Decrease) in Cash and Cash Equivalents Cash and Cash Equivalents at the beginning of the Cash and Cash Equivalents at the end of the year	1,933.90	223.42
Net Increase / (Decrease) in Cash and Cash Equivalents Cash and Cash Equivalents at the beginning of the Cash and Cash Equivalents at the end of the year Components of Cash and Cash Equivalents:	1,933.90 3,123.86	223.42 1,933.90
Net Increase / (Decrease) in Cash and Cash Equivalents Cash and Cash Equivalents at the beginning of the Cash and Cash Equivalents at the end of the year Components of Cash and Cash Equivalents: Cash on Hand	1,933.90	223.42
Net Increase / (Decrease) in Cash and Cash Equivalents Cash and Cash Equivalents at the beginning of the Cash and Cash Equivalents at the end of the year Components of Cash and Cash Equivalents: Cash on Hand Balances with Bank	1,933.90 3,123.86 4.43	223.42 1,933.90
Net Increase / (Decrease) in Cash and Cash Equivalents Cash and Cash Equivalents at the beginning of the Cash and Cash Equivalents at the end of the year Components of Cash and Cash Equivalents: Cash on Hand Balances with Bank Current Accounts	1,933.90 3,123.86 4.43 1,541.46	1,933.90 1.38 1,743.80
Balances with Bank Current Accounts EEFC Account	1,933.90 3,123.86 4.43	223.42 1,933.90
Net Increase / (Decrease) in Cash and Cash Equivalents Cash and Cash Equivalents at the beginning of the Cash and Cash Equivalents at the end of the year Components of Cash and Cash Equivalents: Cash on Hand Balances with Bank Current Accounts	1,933.90 3,123.86 4.43 1,541.46	1,933.90 1.38 1,743.80







- The Board of Directors have, subject to approval of the shareholders, recommended a Final Dividend of Rs.10/- per equity share of Rs 5/- each (i.e.200%).
- 4 The above audited financial results for the quarter and year ended March 31, 2020 have been reviewed and recommended by the Audit Committee at their meeting held on June 23, 2020, and approved by the Board of Directors at their meeting on the same date.
- The audited financial statements have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendment rules thereafter, and presented in accordance with the requirement of SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
- In view of the continuing lockdown situation due to COVID-19 pandemic across the country, which commenced from 22nd March, 2020, the Company has reviewed and analysed the possible effects of the pandemic on its financial statements, particularly for the financial year 2020-2021. There has been no significant impact on the business and profits of the Company for the year ended March 31, 2020. As the Company is in the manufacture and sale of essential products, being mainly pharmaceutical intermediates, the Company was allowed manufacturing activity in the first week of April 2020 at all its locations. By the end of May, 2020 the Company has achieved near optimum production in response to orders on hand, both domestic and exports, which is expected to continue going forward. The offices and Technical Centre employees have been working from home to provide support to the procurement, manufacturing and selling activities. Though the Company is not in position to gauge with certainty the future impact on its operations, the Company expects that the demand for its products from pharmaceuticals sector will continue and, as such, barring unforeseen circumstances there will not be a significant impact of COVID-19 on the operations of the Company for the financial year 2020-21.
 - Also, in assessing the recoverability of receivables and other financial assets, the Company has considered internal and external information up to the date of approval of these financial results. The Company has performed sensitivity analysis on the assumptions used and based on current estimates expects that the carrying amount of these assets will be recovered.
- Fifective April 1, 2019, the Company adopted Ind AS 116 "Leases", applied to all lease contracts existing as on April 1, 2019, using the Modified Retrospective Method, along with the transition option to recognize Right-of-Use asset (ROU) at an amount equal to the lease liability, as provided under Para C8(c)(ii) in Appendix C of Ind AS 116. Accordingly, comparatives for the quarter and year ended March 31 2019, have not been retrospectively adjusted. The effect of this adoption is not material on the profit for the year and earnings per share.
- Pursuant to the Taxation Laws (Amendment) Ordinance 2019, the Company has decided to opt for the reduced tax rate of 22%. The current tax and deferred tax have accordingly been computed, based on the revised rate, inclusive of surcharge and cess, which comes to 25.17%. Consequently, the current tax and deferred tax for the year ended March 31, 2020 is lower by Rs.2,081.41 lakhs and Rs. 1,567.81 lakhs respectively.
- During the year, the Company has disposed of its entire shareholding in its associate, Diamines and Chemicals Ltd. on 18th November, 2019 at a consideration of Rs.3428.27 Lakhs. Subsequent to the disposal, Diamines and Chemicals Ltd. has ceased to be an Associate of the Company from 18th November, 2019. Consequently, the Company has recognised the profit on sale of Investment amounting to Rs. 3284.16 Lakhs under the head 'Exceptional Items'.
- 10 a. The Company is engaged in only one primary business segment, i.e. "Specialty Chemicals", as per Indian Accounting Standards (IND AS) 108 Operating Segment.

b. Secondary segment

Rs. in Lakhs

FOR ALKYL AMINES CHEMICALS LTD.

Particulars	Within	India	Outside India		
	2019-20	2018-19	2019-20	2018-19	
Segment Revenue	80,154.19	67,073.88	19,133.57	17,566.21	
Carrying amount of Segment Assets	74,617.19	70,996.78	3,276.05	3,498.45	
Capital Expenditure	46,743.14	41,884.47	92.80	73.46	

The segment revenue in Geographical Segments considered for disclosure is as follows:

- i. Revenue within India includes sales to customers located within India and Other Operating Revenue earned in India.
- ii. Revenue outside India includes sales to customers located outside India and Other Operating Revenue earned outside India.
- 11 The figures for the quarter ended March 31, 2020 and March 31, 2019 as reported in these financial results are balancing figures between the audited figures in respect of the financial year and the published year to date figures up to the end of the third quarter of the relevant financial year. Also the figures up to the end of third quarter had only been subject to limited review.
- 12 Figures for the previous periods have been regrouped and reclassified, wherever necessary.

Place : Mumbai Date : June 23,2020 YOGESH M
KOTHARI
YOGESH M
KOTHARI
YOGESH M.KOTHARI
CHAIRMAN & MANAGING DIRECTOR



Alkyl Amines Chemicals Limited



Reg. Office: 401-407, Nirman Vyapar Kendra, Plot No. 10, Sector 17, Vashi, Navi Mumbai - 400 703. INDIA Tel.: 022-6794 6600 • Fax: 022-6794 6666 • E-mail : alkyl@alkylamines.com • Web: www.alkylamines.com

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2020

	Rs. in Lakhs (Except per share data)					
			Quarter ended			ended
r.	Particulars	Mar 31, 2020	Dec 31, 2019	Mar 31, 2019	Mar 31, 2020 Mar 31, 201	
lo.		Audited	Unaudited	Audited	Audited	Audited
	Revenue from Operations	23,476.51	25,691.11	23,745.11	99,287.76	84,640.09
١.	Other Income	261.93	216.72	160.55	641.60	230.96
I.	Total Revenue (I+II)	23,738.44	25,907.83	23,905.66	99,929.36	84,871.05
v.	Expenses					
	Cost of Materials Consumed	11,054.36	11,445.87	13,597.46	47,621.68	48,176.61
	Changes in Inventories of Finished Goods	(264.15)	767	574.90	827.78	(2,089.41)
	and Work-in-Progress	,				,
	Employee benefit costs	1,695.74	1,903.79	1,264.50	6,964.15	5,277.90
	Finance Costs	189.32	213.45	332.05	1,025.39	1,476.66
	Depreciation and Amortisation Expense	720.25	680.26	646.40	2,690.98	2,333.68
	Other Expenses	4,232.32	5,067.97	4,470.51	18,161.54	16,839.91
	Total Expenses (IV)	17,627.84	19,327.36	20,885.82	77,291.52	72,015.35
	Share of Net Profit of Associate Company accounted	-	118.42	136.69	438.91	399.73
20	for using Equity Method					
	Profit before Exceptional Items and Tax (III-IV+V)	6,110.60	6,698.89	3,156.53	23,076.75	13,255.43
	Exceptional Items (Refer Note 9)		1,498.39	-	1,498.39	-
	Profit before tax (VI+VII)	6,110.60	8,197.28	3,156.53	24,575.14	13,255.43
(.	Tax Expense :	20. 10.11230.11230.11				
	Current Tax	1,453.14	1,694.50	1,088.60	5,403.55	3,619.81
	Deferred Tax	(266.74)	491.88	175.93	(1,030.04)	1,017.91
	Tax adjustments of earlier years	3.42	(30.40)		69.30	7.32
		1,189.82	2,155.98	1,264.53	4,442.81	4,645.04
_	Net Profit for the Period/Year (VIII-IX)	4,920.78	6,041.30	1,892.00	20,132.33	8,610.39
١.	Other Comprehensive Income/ (Expense)	(40.40)	(45.55)	(4.55.54)		(=)
	a) Items that will not be reclassified to profit or loss	(13.13)	(49.65)	(105.71)	(171.17)	(74.22)
	- Remeasurement gain/(losses) on defined benefit					
	plans			27.00	** **	25.05
	b) Income tax relating to items that will not be	1.82	11.45	37.08	40.38	26.06
	reclassified to profit or loss	0.00	(54.50)	(25.02)	0.00	/21 81)
	c) Items that may be recycled to profit or loss - Deferred gains/(losses) on cash flow hedges	0.86	(64.69)	(25.93)	0.80	(31.81)
		(2.20)			(0.40)	
	d) Income tax relating to items that may be	(0.19)	14.60	9.06	(0.18)	11.12
	reclassified to profit or loss					
	Share of Other comprehensive income / (expense)	-	(6.44)	(4.80)	(12.63)	(14.35)
	(net of tax) of Associate company accounted for using					
	Equity method	4		4		
	Other Comprehensive Income / (Expense) for the	(10.64)	(94.73)	(90.30)	(142.80)	(83.20)
	period/year (Net of Tax)					
	Total Comprehensive Income for the period/year	4,910.14	5,946.57	1,801.70	19,989.53	8,527,19
••	(X+XI)	4,510.14	3,340.37	1,501.70	15,565.55	0,52,00
	V,					15
111.	Paid up Share Capital	1,019.82	1,019.82	1,019.82	1,019.82	H 276 da
	i did up silale capital	1,015.02	1,013.02	1,013.62	1,015.62	(27.02)
v.	Face Value of Share (Rs)	5.00	5.00	5.00	5.00	15.00
1.	Earnings Per Equity Share	5.50	5.50	5.50	5.50	#
			20.52	0.20	00.71	42.27
	Basic (Rs)	24.13	29.62	9.28	98.71	42.22



Notes:

1 CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT MARCH 31, 2020 :

	Rs. in Lak				
	Particulars	As At Mar 31,2020	As At Mar 31,2019		
ASSI	TS	52,2020			
	-Current assets				
(a)	Property, Plant and Equipment	39,224.45	37,551.58		
	Capital Work-In-Progress	4,488.06	4,315.18		
	Right of Use- Lease assets	2,966.40	-		
0005	Intangible Assets	157.04	91.16		
e)	Financial Assets				
~ <i> </i>	(i) Investments		1,552.51		
	(ii) Loans	42.28	45.55		
	(iii) Other Financial Assets	252.77	285.85		
f)	Non-Current Tax Asset (Net)	445.18	356.97		
(g)	Other Non-Current Assets	1,347.64	858.14		
(8)	Other Non-Current Assets	48,923.82	45,056.94		
Curi	ent Assets	10,520.02	,		
(a)	Inventories	8,366.54	10,569.29		
(b)	Financial Assets	5,555.5			
(0)	(i) Trade Receivables	16,422.15	15,263.39		
	(ii) Cash and Cash Equivalent	3,123.86	1,933.91		
		102.58	83.52		
	(iii) Bank Balance	23.46	19.72		
	(iv) Loans		202.40		
	(v) Other Financial Assets	791.79			
(c)	Other Current Assets	584.22	3,131.43		
		29,414.60	31,203.66		
TOT	'AL ASSETS	78,338.42	76,260.60		
Equ (a)	ity Equity Share Capital	1,020.60	1,020.60		
(b)	Other Equity	52,639.06	36,887.11		
1101	BILITIES	53,659.66	36,499.31		
LIA	SILITIES				
Nor	n-Current Liabilities				
(a)	Financial Liabilities				
	Long term Borrowings				
	(i) Secured Borrowings	4,752.02	7,775.37		
	(ii) Unsecured Borrowings	41.46	129.37		
	(iii) Other Financial Liabilities	62.17	-		
(b)	Provisions	278.11	186.30		
(c)	Deferred Tax Liabilities	4,036.27	5,066.33		
(d)	Liabilities for Current Tax (Net)	127.47	419.38		
		9,297.50	13,576.73		
Cur	rent liabilities				
(a)	Financial liabilities				
	(i) Secured Borrowings	3.87	3,508.3		
	(ii) Unsecured Borrowings	-	1,547.00		
	(iii) Lease Liability	5.63	-		
	(iv) Trade Payables	7,077.45	100		
	(v) Other Financial Liabilities	7,390.46	H		
(b)	Other Current Liabilities	341.11			
(c)	Provisions	562.70			
		15,381.26	24,776.10		
TO	TAL EQUITY AND LIABILITIES	78,338.42	76,260.6		





2 CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2020

		Rs. in Lakhs
	ended	ended
Particulars	March 31,	
	2020	March 31, 2019
Cash Flow from Operating Activities		
Profit before tax from continuing operations	24,575.14	13,255.43
Adjustments for :		
Depreciation and Amortization	2,690.98	2,333.68
Gain)/ Loss on Disposal of Assets	144.01	57.65
exceptional Item (Gain on sale of Investment)	(1,498.40)	-
Unrealized Loss/(Gain) on Foreign Exchange	331.17	570.32
nterest expense (Gross)	1,025.39	1,476.66
nterest Income	(179.51)	(31.44)
hare of profit in Associate Company	(438.91)	
Provision no longer required, written back	(118.48)	1
	(220.40)	29.39
Bad Debts written off	84.99	
mployee Stock Options granted		
Operating profit before working capital changes	26,616.38	17,343.22
Adjustments for:		
(Increase) / Decrease in Other Current & Non-Current		
Financial Assets	(553.17)	(193.10)
Increase) / Decrease in Other Current & Non-Current		
Assets	2,057.71	344.13
Increase) / Decrease in Inventories	2,202.75	l control of the cont
	(1,489.93	
Increase) / Decrease in Trade Receivables	(5,321.52	
ncrease / (Decrease) in Trade Payables	1000000	
ncrease / (Decrease) in Other Current Financial Liabilit		1
ncrease / (Decrease) in Other Current Liabilities	(219.18	/
ncrease / (Decrease) in Provisions	17.23	
	24,595.63	
Income taxes paid	(5,812.77	-
Net Cash Flow from Operating Activities	18,782.86	14,420.87
Cash Flow from Investing Activities		
	(7,728.46	(6,904.30)
Purchase of Fixed Assets	15.42	The second second
Disposal of Fixed Assets	175.91	
Interest Income	1/3.91	52.03
(Increase)/ Decrease in Margin Money & Fixed	440.00	15.66
Deposits	(19.06	"
Proceeds from Sale of Investment	3,417.65	
Dividend from Investments in Associate	59.56	
Net cash from Investing Activities	(4,078.98	(6,678.81)
a to the first than Askining		
Cash flow from Financing Activities	(1,073.80	(1,500.69
Interest paid		
Repayment of Non-current Borrowings	(2,919.03	
Repayment of Current Borrowings	(5,051.45	- 1
Increase / (Decrease) in Lease Liabilities	67.80	
Dividend and Dividend Tax Paid	(4,426.10	
Payment of Deferral Sales Tax	(111.34	
Net cash from Financing Activities	(13,513.9	2) (6,031.58
//Danasaskin Cosh and Cash		
Net Increase / (Decrease) in Cash and Cash Equivalents	1,189.9	6 1,710.48
Cash and cash equivalents at the beginning of the year	1,933.9	0 223.42
Cash and Cash Equivalents at the end of the year	3,123.8	6 1,933.90
Components of Cash and Cash Equivalents :		
Cash on Hand	4.4	3 1.38
Balances with Bank	1,541.4	1,743.80
Current Accounts		1
EEFC Account	487.9	1/9.10
Fixed Deposit Accounts (with original maturity of		
less than 3 months)	1,090.0	
	3,123.8	1,933.90





- 3 The Board of Directors have, subject to approval of the shareholders, recommended a Final Dividend of Rs.10/- per equity share of Rs 5/- each (i.e.200%).
- 4 The above audited financial results for the quarter and year ended March 31, 2020 have been reviewed and recommended by the Audit Committee at their meeting held on June 23, 2020, and approved by the Board of Directors at their meeting on the same date.
- The audited financial statements have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendment rules thereafter, and presented in accordance with the requirement of SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
- In view of the continuing lockdown situation due to COVID-19 pandemic across the country, which commenced from 22nd March, 2020, the Company has reviewed and analysed the possible effects of the pandemic on its financial statements, particularly for the financial year 2020-2021. There has been no significant impact on the business and profits of the Company for the year ended March 31, 2020. As the Company is in the manufacture and sale of essential products, being mainly pharmaceutical intermediates, the Company was allowed manufacturing activity in the first week of April 2020 at all its locations. By the end of May, 2020 the Company has achieved near optimum production in response to orders on hand, both domestic and exports, which is expected to continue going forward. The offices and Technical Centre employees have been working from home to provide support to the procurement, manufacturing and selling activities. Though the Company is not in position to gauge with certainty the future impact on its operations, the Company expects that the demand for its products from pharmaceuticals sector will continue and, as such, barring unforeseen circumstances there will not be a significant impact of COVID-19 on the operations of the Company for the financial year 2020-21.
 - Also, in assessing the recoverability of receivables and other financial assets, the Company has considered internal and external information up to the date of approval of these financial results. The Company has performed sensitivity analysis on the assumptions used and based on current estimates expects that the carrying amount of these assets will be recovered.
- 7 Effective April 1, 2019, the Company adopted Ind AS 116 "Leases", applied to all lease contracts existing as on April 1, 2019, using the Modified Retrospective Method, along with the transition option to recognize Right-of-Use asset (ROU) at an amount equal to the lease liability, as provided under Para C8(c)(ii) in Appendix C of Ind AS 116. Accordingly, comparatives for the quarter and year ended March 31 2019, have not been retrospectively adjusted. The effect of this adoption is not material on the profit for the year and earnings per share.
- Pursuant to the Taxation Laws (Amendment) Ordinance 2019, the Company has decided to opt for the reduced tax rate of 22%. The current tax and deferred tax have accordingly been computed, based on the revised rate, inclusive of surcharge and cess, which comes to 25.17%. Consequently, the current tax and deferred tax for the year ended March 31, 2020 is lower by Rs.2,081.41 lakhs and Rs. 1,567.81 lakhs respectively
- 9 During the year, the Company has disposed of its entire shareholding in its associate, Diamines and Chemicals Ltd. on 18th November, 2019 at a consideration of Rs.3428.27 Lakhs. Subsequent to the disposal, Diamines and Chemicals Ltd. has ceased to be an Associate of the Company from 18th November, 2019. Consequently, the Company has recognised the profit on sale of Investment amounting to Rs. 1498.39 Lakhs under the head 'Exceptional Items'.
- 10 a. The Company is engaged in only one primary business segment, i.e. "Specialty Chemicals", as per Indian Accounting Standards (IND AS) 108 Operating Segment.

b. Secondary segment

Rs. in Lakhs

Particulars	Within	India	Outside India		
	2019-20	2018-19	2019-20	2018-19	
Segment Revenue	80,154.19	67,073.88	19,133.57	17,566.21	
Carrying amount of Segment Assets	74,617.19	70,996.78	3,276.05	3,498.45	
Capital Expenditure	46,743.14	41,884.47	92.80	73.46	

The segment revenue in Geographical Segments considered for disclosure is as follows:

- i. Revenue within India includes sales to customers located within India and Other Operating Revenue earned in India.
- ii. Revenue outside India includes sales to customers located outside India and Other Operating Revenue earned outside India.
- 11 The figures for the quarter ended March 31, 2020 as reported in these financial results are balancing figures between the audited figures in respect of the financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also the figures upto the end of third quarter had only been subject to limited review.
- As permitted under Regulation 33(3)(b)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company had opted to publish only Standalone financial results during the interim periods for the previous nine months period ended December 31 2018. Accordingly, the consolidated financial results have been presented only for the year ended March 31, 2019 and hence, the figures for the corresponding quarter ended March 31, 2019 are the balancing figures between audited figures in respect of the full financial year and the Board approved year-to-date figures for the nine months period ended December 31, 2018.

13 Figures for the previous periods have been regrouped and reclassified, wherever necessary.

Place : Mumbai Date : June 23,2020



FOR ALKYL AMINES CHEMICALS LTD.

YOGESH M

Conference on the Co

YOGESH M.KOTHARI CHAIRMAN & MANAGING DIRECTOR